Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Annals of Translational Medicine|August 25, 2021
Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphomaYao Zhang, Yizhen Liu, Zuguang Xia, et al.
Ecotoxicology and Environmental Safety|February 4, 2024
Associations of prenatal exposure to per- and polyfluoroalkyl substances and fetal sex hormones in the Guangxi Zhuang Birth Cohort Study: Greater effect of long-chain PFASQian Liao, Huishen Huang, Peng Tang, et al.
Hematological Oncology|July 21, 2026
Clinical Impact of BTK Inhibitor Exposure in LymphGen-Defined MCD Diffuse Large B-Cell LymphomaShiyu Jiang, Yizhen Liu, Ran Wei, et al.
Blood Cancer Journal|July 1, 2026
Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II studyQunling Zhang, Shiyu Jiang, Ran Wei, et al.
Ecotoxicology and Environmental Safety|November 11, 2023
Effects of prenatal single and mixed bisphenol exposure on bone mineral density in preschool children: A population-based prospective cohort studyJun Liang, Lixiang Pang, Chunxiu Yang, et al.
International Journal of Nanomedicine|March 28, 2014
Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancerSi Sun, Lichen Tang, Jian Zhang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 22, 2026
Nano-sized DNase scavenges cell-free DNA for acute lung injury treatmentRuijie Chen, Yitianhe Xu, Zhanzheng Ye, et al.
Aging|December 8, 2020
The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistanceYizhen Liu, Juan J Gu, Ling Yang, et al.
Mediterranean Journal of Hematology and Infectious Diseases|September 19, 2022
Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell LymphomaGuang-Liang Chen, Doudou Li, Sufen Cao, et al.
BMC Cancer|March 15, 2017
A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancerXin Liu, Weijian Guo, Wen Zhang, et al.
Pageof 10